Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. (PetMeds) (NASDAQ: PETS) generates a steady flow of corporate, financial, and operational news that is relevant to investors, analysts, and pet healthcare observers. As a national online pet pharmacy and parent company of PetCareRx, PetMeds regularly issues press releases and SEC reports covering its business performance, governance, regulatory status, and strategic developments.
News about PetMed Express often includes updates on its financial reporting, such as the filing of its Annual Report on Form 10-K and preliminary revenue information for fiscal quarters. The company has reported on investigations by its Audit Committee into accounting and control matters, the resulting restatement of certain prior financial statements, and the identification of material weaknesses in internal control over financial reporting. Related news items also cover notices from Nasdaq regarding delayed SEC filings and the company’s plans to regain compliance with listing requirements.
Corporate governance and leadership changes are another frequent news theme. PetMed Express has announced the resignation of senior executives, the appointment of an interim Chief Executive Officer and an interim principal financial officer, and the addition of independent directors with audit and financial expertise to its board. These updates provide insight into how the company is addressing oversight, financial governance, and board composition.
Strategic and transactional news includes unsolicited, non-binding acquisition proposals from investment firms such as SilverCape Investments Limited and Cardone Ventures, each expressing interest in acquiring all outstanding shares of PetMed Express at a specified cash price per share, subject to customary conditions. The company has also highlighted partnerships and initiatives in the pet healthcare community, such as fundraising efforts with the myBalto Foundation to support emergency veterinary care. Together, these news items offer a detailed view of PetMed Express’s evolving business, governance, and strategic landscape.
PetMed Express (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2021, on July 26, 2021, at 8:00 A.M. Eastern Time.
A conference call to discuss the results will follow at 8:30 A.M. ET, and is accessible to the public by dialing (888) 455-1758 or (203) 827-7025. A replay of the call will be available from July 26 at 10:00 A.M. until August 9, 2021.
Founded in 1996, PetMed Express delivers prescription and non-prescription medications for pets directly to consumers.
PetMed Express reported strong fiscal 2021 results, showing an 8.8% increase in net sales to $309.2 million and a 18.4% increase in net income to $30.6 million. Despite fourth-quarter challenges, with a 3.5% decrease in net sales to $71.7 million, the overall year reflected a successful pivot to e-commerce driven by COVID-19. The company acquired 443,000 new customers and improved average order size. An increased quarterly dividend of $0.30 per share was declared, reflecting ongoing confidence in future growth.
PetMed Express (PETS) will announce its financial results for the fiscal year ending March 31, 2021, on May 3, 2021, at 8:00 A.M. ET. CEO Menderes Akdag will host a conference call at 8:30 A.M. ET to discuss the results. The call is accessible to the public by dialing (888) 455-1758 or (203) 827-7025. A replay of the call will be available until May 17, 2021. Founded in 1996, PetMed Express is a leading pet pharmacy in the U.S. offering medications and health products for pets through its toll-free number and website.
PetMed Express, Inc. (NASDAQ: PETS) reported a 10% increase in quarterly net sales, reaching $65.9 million for the quarter ended December 31, 2020, compared to $59.9 million in the same quarter of 2019. Diluted EPS rose to $0.38 from $0.34. Year-to-date sales were $237.5 million, up 13.2%. Reorder sales climbed 11.9% to $60.2 million for the quarter. A quarterly dividend of $0.28 per share was declared, payable on February 12, 2021. The company continues to focus on enhancing customer experience and expanding its digital offerings.
PetMed Express will release its Q3 financial results for the period ending December 31, 2020, on January 19, 2021, at 8:00 A.M. Eastern Time. Following this, CEO Menderes Akdag will host a conference call at 8:30 A.M. Eastern Time to discuss the results. Participants can join the call by dialing (888) 455-1758 or (203) 827-7025 and must provide the passcode PETMEDS. For those unable to attend live, a replay will be available until February 2, 2021.
PetMed Express reported a strong performance for Q2 2020 with net sales reaching $75.4 million, up 7.9% from $69.9 million in Q2 2019. The net income rose 26.2% to $8.4 million or $0.42 per diluted share. Reorder sales also saw a significant increase of 9.6% to $67.8 million. With gross margins improving from 27.8% to 30.5%, the company is set to enhance its digital presence by redesigning its website and mobile app. A quarterly dividend of $0.28 per share was declared, payable on November 20, 2020.
PetMed Express (NASDAQ: PETS) is scheduled to announce its financial results for Q2 2020 on October 26, 2020, at 8:00 A.M. ET. CEO Menderes Akdag will host a conference call at 8:30 A.M. ET to discuss these results. The call is public and can be accessed at (888) 455-1758 with the passcode PETMEDS. A replay will be available from 10:00 A.M. ET on the same day until November 9, 2020. PetMed Express is recognized as America’s Largest and Most Trusted Pet Pharmacy, providing prescription and non-prescription pet medications directly to consumers.
PetMed Express (NASDAQ: PETS) reported a 20% increase in net sales for the first quarter ended June 30, 2020, totaling $96.2 million, up from $80.0 million in the same period last year. Net income rose 47% to $7.8 million, or $0.39 diluted per share. New order sales grew 29% to $15.8 million, while reorder sales increased 19% to $80.4 million. The company acquired 186,000 new customers, enhancing its average order size to $89. A quarterly dividend of $0.28 per share has been declared, payable on August 7, 2020.
PetMed Express (NASDAQ: PETS) will report its financial results for Q1 2020 on July 20, 2020, at 8:00 A.M. ET. A conference call led by CEO Menderes Akdag will follow at 8:30 A.M. ET, accessible via phone at (888) 455-1758 or (203) 827-7025 with passcode PETMEDS. For those unable to attend live, a replay will be available from 10:00 A.M. ET on the same day until August 3, 2020.
Founded in 1996, PetMed Express is a leading online pet pharmacy, providing a range of medications and health products for pets.